nodes	percent_of_prediction	percent_of_DWPC	metapath
Metipranolol—Lacrimation—Fluorouracil—urinary bladder cancer	0.0241	0.0241	CcSEcCtD
Metipranolol—Blepharitis—Fluorouracil—urinary bladder cancer	0.0231	0.0231	CcSEcCtD
Metipranolol—Myalgia—Valrubicin—urinary bladder cancer	0.0184	0.0184	CcSEcCtD
Metipranolol—Discomfort—Valrubicin—urinary bladder cancer	0.0182	0.0182	CcSEcCtD
Metipranolol—Photophobia—Thiotepa—urinary bladder cancer	0.0161	0.0161	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Valrubicin—urinary bladder cancer	0.0161	0.0161	CcSEcCtD
Metipranolol—Lacrimation increased—Fluorouracil—urinary bladder cancer	0.0154	0.0154	CcSEcCtD
Metipranolol—Vision blurred—Mitomycin—urinary bladder cancer	0.014	0.014	CcSEcCtD
Metipranolol—Photophobia—Fluorouracil—urinary bladder cancer	0.0133	0.0133	CcSEcCtD
Metipranolol—Cough—Mitomycin—urinary bladder cancer	0.013	0.013	CcSEcCtD
Metipranolol—Hypertension—Mitomycin—urinary bladder cancer	0.0129	0.0129	CcSEcCtD
Metipranolol—Asthenia—Valrubicin—urinary bladder cancer	0.0127	0.0127	CcSEcCtD
Metipranolol—Discomfort—Mitomycin—urinary bladder cancer	0.0125	0.0125	CcSEcCtD
Metipranolol—Oedema—Mitomycin—urinary bladder cancer	0.0122	0.0122	CcSEcCtD
Metipranolol—Lacrimation—Epirubicin—urinary bladder cancer	0.0117	0.0117	CcSEcCtD
Metipranolol—Dizziness—Valrubicin—urinary bladder cancer	0.0117	0.0117	CcSEcCtD
Metipranolol—Rash—Valrubicin—urinary bladder cancer	0.0111	0.0111	CcSEcCtD
Metipranolol—Dermatitis—Valrubicin—urinary bladder cancer	0.0111	0.0111	CcSEcCtD
Metipranolol—Headache—Valrubicin—urinary bladder cancer	0.0111	0.0111	CcSEcCtD
Metipranolol—Lacrimation—Doxorubicin—urinary bladder cancer	0.0109	0.0109	CcSEcCtD
Metipranolol—Dyspnoea—Mitomycin—urinary bladder cancer	0.0108	0.0108	CcSEcCtD
Metipranolol—Somnolence—Mitomycin—urinary bladder cancer	0.0108	0.0108	CcSEcCtD
Metipranolol—Nausea—Valrubicin—urinary bladder cancer	0.0105	0.0105	CcSEcCtD
Metipranolol—Conjunctivitis—Thiotepa—urinary bladder cancer	0.00932	0.00932	CcSEcCtD
Metipranolol—Epistaxis—Thiotepa—urinary bladder cancer	0.00904	0.00904	CcSEcCtD
Metipranolol—Asthenia—Mitomycin—urinary bladder cancer	0.00873	0.00873	CcSEcCtD
Metipranolol—Angina pectoris—Fluorouracil—urinary bladder cancer	0.00867	0.00867	CcSEcCtD
Metipranolol—Dizziness—Mitomycin—urinary bladder cancer	0.00804	0.00804	CcSEcCtD
Metipranolol—Acute coronary syndrome—Gemcitabine—urinary bladder cancer	0.00795	0.00795	CcSEcCtD
Metipranolol—Myocardial infarction—Gemcitabine—urinary bladder cancer	0.00791	0.00791	CcSEcCtD
Metipranolol—Acute coronary syndrome—Fluorouracil—urinary bladder cancer	0.00782	0.00782	CcSEcCtD
Metipranolol—Myocardial infarction—Fluorouracil—urinary bladder cancer	0.00777	0.00777	CcSEcCtD
Metipranolol—Conjunctivitis—Fluorouracil—urinary bladder cancer	0.00771	0.00771	CcSEcCtD
Metipranolol—Rash—Mitomycin—urinary bladder cancer	0.00767	0.00767	CcSEcCtD
Metipranolol—Dermatitis—Mitomycin—urinary bladder cancer	0.00766	0.00766	CcSEcCtD
Metipranolol—Headache—Mitomycin—urinary bladder cancer	0.00762	0.00762	CcSEcCtD
Metipranolol—Lacrimation increased—Epirubicin—urinary bladder cancer	0.00749	0.00749	CcSEcCtD
Metipranolol—Epistaxis—Fluorouracil—urinary bladder cancer	0.00748	0.00748	CcSEcCtD
Metipranolol—Acute coronary syndrome—Cisplatin—urinary bladder cancer	0.00741	0.00741	CcSEcCtD
Metipranolol—Myocardial infarction—Cisplatin—urinary bladder cancer	0.00737	0.00737	CcSEcCtD
Metipranolol—Tension—Thiotepa—urinary bladder cancer	0.00735	0.00735	CcSEcCtD
Metipranolol—Conjunctivitis—Cisplatin—urinary bladder cancer	0.00731	0.00731	CcSEcCtD
Metipranolol—Nervousness—Thiotepa—urinary bladder cancer	0.00728	0.00728	CcSEcCtD
Metipranolol—Rhinitis—Gemcitabine—urinary bladder cancer	0.00726	0.00726	CcSEcCtD
Metipranolol—Nausea—Mitomycin—urinary bladder cancer	0.00722	0.00722	CcSEcCtD
Metipranolol—Rhinitis—Fluorouracil—urinary bladder cancer	0.00714	0.00714	CcSEcCtD
Metipranolol—Vision blurred—Thiotepa—urinary bladder cancer	0.00706	0.00706	CcSEcCtD
Metipranolol—Lacrimation increased—Doxorubicin—urinary bladder cancer	0.00693	0.00693	CcSEcCtD
Metipranolol—Bradycardia—Cisplatin—urinary bladder cancer	0.00687	0.00687	CcSEcCtD
Metipranolol—Acute coronary syndrome—Etoposide—urinary bladder cancer	0.00679	0.00679	CcSEcCtD
Metipranolol—Myocardial infarction—Etoposide—urinary bladder cancer	0.00675	0.00675	CcSEcCtD
Metipranolol—Cough—Thiotepa—urinary bladder cancer	0.00654	0.00654	CcSEcCtD
Metipranolol—Visual impairment—Cisplatin—urinary bladder cancer	0.0065	0.0065	CcSEcCtD
Metipranolol—Hypertension—Thiotepa—urinary bladder cancer	0.00647	0.00647	CcSEcCtD
Metipranolol—Myalgia—Thiotepa—urinary bladder cancer	0.00638	0.00638	CcSEcCtD
Metipranolol—Anxiety—Thiotepa—urinary bladder cancer	0.00636	0.00636	CcSEcCtD
Metipranolol—Abnormal vision—Epirubicin—urinary bladder cancer	0.00602	0.00602	CcSEcCtD
Metipranolol—Vision blurred—Fluorouracil—urinary bladder cancer	0.00584	0.00584	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.00557	0.00557	CcSEcCtD
Metipranolol—Abnormal vision—Doxorubicin—urinary bladder cancer	0.00557	0.00557	CcSEcCtD
Metipranolol—Vision blurred—Cisplatin—urinary bladder cancer	0.00554	0.00554	CcSEcCtD
Metipranolol—Cough—Gemcitabine—urinary bladder cancer	0.0055	0.0055	CcSEcCtD
Metipranolol—Hypertension—Gemcitabine—urinary bladder cancer	0.00544	0.00544	CcSEcCtD
Metipranolol—Somnolence—Thiotepa—urinary bladder cancer	0.00544	0.00544	CcSEcCtD
Metipranolol—Myalgia—Gemcitabine—urinary bladder cancer	0.00537	0.00537	CcSEcCtD
Metipranolol—Discomfort—Gemcitabine—urinary bladder cancer	0.0053	0.0053	CcSEcCtD
Metipranolol—Myalgia—Fluorouracil—urinary bladder cancer	0.00528	0.00528	CcSEcCtD
Metipranolol—Discomfort—Fluorouracil—urinary bladder cancer	0.00521	0.00521	CcSEcCtD
Metipranolol—Oedema—Gemcitabine—urinary bladder cancer	0.00514	0.00514	CcSEcCtD
Metipranolol—Oedema—Fluorouracil—urinary bladder cancer	0.00506	0.00506	CcSEcCtD
Metipranolol—Myalgia—Cisplatin—urinary bladder cancer	0.005	0.005	CcSEcCtD
Metipranolol—Anxiety—Cisplatin—urinary bladder cancer	0.00499	0.00499	CcSEcCtD
Metipranolol—Discomfort—Cisplatin—urinary bladder cancer	0.00494	0.00494	CcSEcCtD
Metipranolol—Oedema—Cisplatin—urinary bladder cancer	0.0048	0.0048	CcSEcCtD
Metipranolol—Cough—Etoposide—urinary bladder cancer	0.0047	0.0047	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.00469	0.00469	CcSEcCtD
Metipranolol—Hypertension—Etoposide—urinary bladder cancer	0.00465	0.00465	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00461	0.00461	CcSEcCtD
Metipranolol—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00459	0.00459	CcSEcCtD
Metipranolol—Somnolence—Gemcitabine—urinary bladder cancer	0.00457	0.00457	CcSEcCtD
Metipranolol—Discomfort—Etoposide—urinary bladder cancer	0.00453	0.00453	CcSEcCtD
Metipranolol—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00451	0.00451	CcSEcCtD
Metipranolol—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00451	0.00451	CcSEcCtD
Metipranolol—Somnolence—Fluorouracil—urinary bladder cancer	0.0045	0.0045	CcSEcCtD
Metipranolol—Asthenia—Thiotepa—urinary bladder cancer	0.00439	0.00439	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00437	0.00437	CcSEcCtD
Metipranolol—Dyspnoea—Cisplatin—urinary bladder cancer	0.00428	0.00428	CcSEcCtD
Metipranolol—Angina pectoris—Epirubicin—urinary bladder cancer	0.00422	0.00422	CcSEcCtD
Metipranolol—Bronchitis—Epirubicin—urinary bladder cancer	0.00416	0.00416	CcSEcCtD
Metipranolol—Dizziness—Thiotepa—urinary bladder cancer	0.00404	0.00404	CcSEcCtD
Metipranolol—Conjunctivitis—Methotrexate—urinary bladder cancer	0.00401	0.00401	CcSEcCtD
Metipranolol—Dyspnoea—Etoposide—urinary bladder cancer	0.00392	0.00392	CcSEcCtD
Metipranolol—Somnolence—Etoposide—urinary bladder cancer	0.00391	0.00391	CcSEcCtD
Metipranolol—Angina pectoris—Doxorubicin—urinary bladder cancer	0.0039	0.0039	CcSEcCtD
Metipranolol—Epistaxis—Methotrexate—urinary bladder cancer	0.00389	0.00389	CcSEcCtD
Metipranolol—Rash—Thiotepa—urinary bladder cancer	0.00386	0.00386	CcSEcCtD
Metipranolol—Bronchitis—Doxorubicin—urinary bladder cancer	0.00385	0.00385	CcSEcCtD
Metipranolol—Dermatitis—Thiotepa—urinary bladder cancer	0.00385	0.00385	CcSEcCtD
Metipranolol—Headache—Thiotepa—urinary bladder cancer	0.00383	0.00383	CcSEcCtD
Metipranolol—Conjunctivitis—Epirubicin—urinary bladder cancer	0.00375	0.00375	CcSEcCtD
Metipranolol—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00373	0.00373	CcSEcCtD
Metipranolol—Asthenia—Gemcitabine—urinary bladder cancer	0.00369	0.00369	CcSEcCtD
Metipranolol—Epistaxis—Epirubicin—urinary bladder cancer	0.00364	0.00364	CcSEcCtD
Metipranolol—Nausea—Thiotepa—urinary bladder cancer	0.00363	0.00363	CcSEcCtD
Metipranolol—Visual impairment—Methotrexate—urinary bladder cancer	0.00357	0.00357	CcSEcCtD
Metipranolol—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00353	0.00353	CcSEcCtD
Metipranolol—Bradycardia—Epirubicin—urinary bladder cancer	0.00353	0.00353	CcSEcCtD
Metipranolol—Rhinitis—Epirubicin—urinary bladder cancer	0.00348	0.00348	CcSEcCtD
Metipranolol—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.00347	0.00347	CcSEcCtD
Metipranolol—Asthenia—Cisplatin—urinary bladder cancer	0.00344	0.00344	CcSEcCtD
Metipranolol—Epistaxis—Doxorubicin—urinary bladder cancer	0.00337	0.00337	CcSEcCtD
Metipranolol—Dizziness—Fluorouracil—urinary bladder cancer	0.00335	0.00335	CcSEcCtD
Metipranolol—Visual impairment—Epirubicin—urinary bladder cancer	0.00334	0.00334	CcSEcCtD
Metipranolol—Bradycardia—Doxorubicin—urinary bladder cancer	0.00327	0.00327	CcSEcCtD
Metipranolol—Rash—Gemcitabine—urinary bladder cancer	0.00324	0.00324	CcSEcCtD
Metipranolol—Dermatitis—Gemcitabine—urinary bladder cancer	0.00324	0.00324	CcSEcCtD
Metipranolol—Hypersensitivity—Etoposide—urinary bladder cancer	0.00324	0.00324	CcSEcCtD
Metipranolol—Headache—Gemcitabine—urinary bladder cancer	0.00322	0.00322	CcSEcCtD
Metipranolol—Rhinitis—Doxorubicin—urinary bladder cancer	0.00322	0.00322	CcSEcCtD
Metipranolol—Rash—Fluorouracil—urinary bladder cancer	0.00319	0.00319	CcSEcCtD
Metipranolol—Dermatitis—Fluorouracil—urinary bladder cancer	0.00319	0.00319	CcSEcCtD
Metipranolol—Headache—Fluorouracil—urinary bladder cancer	0.00317	0.00317	CcSEcCtD
Metipranolol—Asthenia—Etoposide—urinary bladder cancer	0.00315	0.00315	CcSEcCtD
Metipranolol—Visual impairment—Doxorubicin—urinary bladder cancer	0.00309	0.00309	CcSEcCtD
Metipranolol—Nausea—Gemcitabine—urinary bladder cancer	0.00306	0.00306	CcSEcCtD
Metipranolol—Vision blurred—Methotrexate—urinary bladder cancer	0.00304	0.00304	CcSEcCtD
Metipranolol—Rash—Cisplatin—urinary bladder cancer	0.00302	0.00302	CcSEcCtD
Metipranolol—Dermatitis—Cisplatin—urinary bladder cancer	0.00302	0.00302	CcSEcCtD
Metipranolol—Nausea—Fluorouracil—urinary bladder cancer	0.003	0.003	CcSEcCtD
Metipranolol—Tension—Epirubicin—urinary bladder cancer	0.00296	0.00296	CcSEcCtD
Metipranolol—Nervousness—Epirubicin—urinary bladder cancer	0.00293	0.00293	CcSEcCtD
Metipranolol—Dizziness—Etoposide—urinary bladder cancer	0.00291	0.00291	CcSEcCtD
Metipranolol—Nausea—Cisplatin—urinary bladder cancer	0.00285	0.00285	CcSEcCtD
Metipranolol—Vision blurred—Epirubicin—urinary bladder cancer	0.00284	0.00284	CcSEcCtD
Metipranolol—Cough—Methotrexate—urinary bladder cancer	0.00281	0.00281	CcSEcCtD
Metipranolol—Rash—Etoposide—urinary bladder cancer	0.00277	0.00277	CcSEcCtD
Metipranolol—Dermatitis—Etoposide—urinary bladder cancer	0.00277	0.00277	CcSEcCtD
Metipranolol—Headache—Etoposide—urinary bladder cancer	0.00275	0.00275	CcSEcCtD
Metipranolol—Myalgia—Methotrexate—urinary bladder cancer	0.00275	0.00275	CcSEcCtD
Metipranolol—Tension—Doxorubicin—urinary bladder cancer	0.00274	0.00274	CcSEcCtD
Metipranolol—Discomfort—Methotrexate—urinary bladder cancer	0.00271	0.00271	CcSEcCtD
Metipranolol—Nervousness—Doxorubicin—urinary bladder cancer	0.00271	0.00271	CcSEcCtD
Metipranolol—Palpitations—Epirubicin—urinary bladder cancer	0.00267	0.00267	CcSEcCtD
Metipranolol—Cough—Epirubicin—urinary bladder cancer	0.00263	0.00263	CcSEcCtD
Metipranolol—Vision blurred—Doxorubicin—urinary bladder cancer	0.00263	0.00263	CcSEcCtD
Metipranolol—Nausea—Etoposide—urinary bladder cancer	0.00261	0.00261	CcSEcCtD
Metipranolol—Hypertension—Epirubicin—urinary bladder cancer	0.00261	0.00261	CcSEcCtD
Metipranolol—Myalgia—Epirubicin—urinary bladder cancer	0.00257	0.00257	CcSEcCtD
Metipranolol—Anxiety—Epirubicin—urinary bladder cancer	0.00256	0.00256	CcSEcCtD
Metipranolol—Discomfort—Epirubicin—urinary bladder cancer	0.00254	0.00254	CcSEcCtD
Metipranolol—Palpitations—Doxorubicin—urinary bladder cancer	0.00247	0.00247	CcSEcCtD
Metipranolol—Oedema—Epirubicin—urinary bladder cancer	0.00246	0.00246	CcSEcCtD
Metipranolol—Cough—Doxorubicin—urinary bladder cancer	0.00244	0.00244	CcSEcCtD
Metipranolol—Hypertension—Doxorubicin—urinary bladder cancer	0.00241	0.00241	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.0024	0.0024	CcSEcCtD
Metipranolol—Myalgia—Doxorubicin—urinary bladder cancer	0.00238	0.00238	CcSEcCtD
Metipranolol—Anxiety—Doxorubicin—urinary bladder cancer	0.00237	0.00237	CcSEcCtD
Metipranolol—Discomfort—Doxorubicin—urinary bladder cancer	0.00235	0.00235	CcSEcCtD
Metipranolol—Dyspnoea—Methotrexate—urinary bladder cancer	0.00235	0.00235	CcSEcCtD
Metipranolol—Somnolence—Methotrexate—urinary bladder cancer	0.00234	0.00234	CcSEcCtD
Metipranolol—Oedema—Doxorubicin—urinary bladder cancer	0.00228	0.00228	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00224	0.00224	CcSEcCtD
Metipranolol—Dyspnoea—Epirubicin—urinary bladder cancer	0.0022	0.0022	CcSEcCtD
Metipranolol—Somnolence—Epirubicin—urinary bladder cancer	0.00219	0.00219	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.00208	0.00208	CcSEcCtD
Metipranolol—Dyspnoea—Doxorubicin—urinary bladder cancer	0.00203	0.00203	CcSEcCtD
Metipranolol—Somnolence—Doxorubicin—urinary bladder cancer	0.00203	0.00203	CcSEcCtD
Metipranolol—Hypersensitivity—Methotrexate—urinary bladder cancer	0.00194	0.00194	CcSEcCtD
Metipranolol—Asthenia—Methotrexate—urinary bladder cancer	0.00189	0.00189	CcSEcCtD
Metipranolol—Hypersensitivity—Epirubicin—urinary bladder cancer	0.00181	0.00181	CcSEcCtD
Metipranolol—Asthenia—Epirubicin—urinary bladder cancer	0.00177	0.00177	CcSEcCtD
Metipranolol—Dizziness—Methotrexate—urinary bladder cancer	0.00174	0.00174	CcSEcCtD
Metipranolol—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.00168	0.00168	CcSEcCtD
Metipranolol—Rash—Methotrexate—urinary bladder cancer	0.00166	0.00166	CcSEcCtD
Metipranolol—Dermatitis—Methotrexate—urinary bladder cancer	0.00166	0.00166	CcSEcCtD
Metipranolol—Headache—Methotrexate—urinary bladder cancer	0.00165	0.00165	CcSEcCtD
Metipranolol—Asthenia—Doxorubicin—urinary bladder cancer	0.00163	0.00163	CcSEcCtD
Metipranolol—Dizziness—Epirubicin—urinary bladder cancer	0.00163	0.00163	CcSEcCtD
Metipranolol—Nausea—Methotrexate—urinary bladder cancer	0.00156	0.00156	CcSEcCtD
Metipranolol—Rash—Epirubicin—urinary bladder cancer	0.00155	0.00155	CcSEcCtD
Metipranolol—Dermatitis—Epirubicin—urinary bladder cancer	0.00155	0.00155	CcSEcCtD
Metipranolol—Headache—Epirubicin—urinary bladder cancer	0.00154	0.00154	CcSEcCtD
Metipranolol—Dizziness—Doxorubicin—urinary bladder cancer	0.00151	0.00151	CcSEcCtD
Metipranolol—Nausea—Epirubicin—urinary bladder cancer	0.00146	0.00146	CcSEcCtD
Metipranolol—Rash—Doxorubicin—urinary bladder cancer	0.00144	0.00144	CcSEcCtD
Metipranolol—Dermatitis—Doxorubicin—urinary bladder cancer	0.00144	0.00144	CcSEcCtD
Metipranolol—Headache—Doxorubicin—urinary bladder cancer	0.00143	0.00143	CcSEcCtD
Metipranolol—Nausea—Doxorubicin—urinary bladder cancer	0.00135	0.00135	CcSEcCtD
